U
ELDN icon

UBS’s Eledon Pharmaceuticals ELDN Stock Holding History

UBS’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$16K Buy
+7
New +$19.9K ﹤0.01% 8273

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

UBS's ELDN Position: Q3 2014 in Review

UBS opened a new position in Eledon Pharmaceuticals (ELDN) in Q3 2014: 7 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #8273 among its holdings.

27 funds tracked by Wall St. Rank hold ELDN as of Q3 2014.

  • UBS held 7 shares of Eledon Pharmaceuticals worth $16K as of Q3 2014.
  • Eledon Pharmaceuticals was a new UBS position in Q3 2014.
  • Eledon Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8273 holding.
  • 27 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.